News and Comments

SEQUENOM CURRENT STATUS

  Friday, November 15, 2013

SEQUENOM  More...

SEQUENOM CURRENT STATUS

  Friday, November 15, 2013

SEQUENOM  More...

GERON PROMISING NEWS POSE NO THREAT TO INCYTE

  Thursday, November 07, 2013

Good news has come from Geron (GERN) - a firm we liked and mentioned several times as a reference where researchers and firms involved in embryonic stem cells resorted to when they faced problems and needed help. Although Geron had an excellent research and numerous patents covering many aspects of embryonic stem cells, the firm decided to dispose of its stem cell program and pursue its drug development program, which among various approaches, most of it revolve around the telomere, which is tips the ends of the chromosomes.    More...

IMMUNOGEN: OPINIONS ARE BEING EXPRESSED. HERE IS OUR VIEW

  Tuesday, November 05, 2013

Stopping Phase 2 trial of its ADC product IMGN901 on patients with non-small-cell lung cancer is  most probably a temporary setback, which we believe would have no negative long-term impact on ImmunoGen’s (IMGN) success and growth. The failure of the drug has nothing to do with ImmunoGen’s TAP technology that has been validated through the approval of HER2 positive breast cancer ADC product Kadcyla® and through many years of experimentation.  More...


Recent News_and_Comments


Archive


Tags